Controversies in clinical trials of cancer vaccines for Glioblastoma

Journal of Vaccines and Vaccination

Volumn 4, Issue 1, 2013, Pages 171-

  Terasaki, Mizuhiko ^a   Murotani, Kenta ^b   Narita, Yoshitaka ^c   Nishikawa, Ryo ^d   Sasada, Tetsuro ^a   Yamada, Akira ^a,e   Itoh, Kyogo ^a   Morioka, Motohiro ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^e Research Centre for Innovative Cancer Therapy   (Japan)

Author keywords

Best recommended treatment; Clinical trial; Glioblastoma; Tumour progression

Indexed keywords

EID: 84879911768     PISSN: None     EISSN: 21577560     Source Type: Journal    
DOI: 10.4172/2157-7560.1000171     Document Type: Article

References (48)

1. Stupp R, Hegi ME, Mason WP, Van den Bent MJ, Taphoorn MJ, et al. (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466.
2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109.
3. Stupp R, Hegi ME, Van den Bent MJ, Mason WP, Weller M, et al. (2006) Changing paradigms--an update on the multidisciplinary management of malignant glioma. Oncologist 11: 165-180.
4. Lowenstein PR (2010) Cancer vaccines in glioma: how to balance the challenges of small trials, efficiency, and potential adverse events. J Clin Oncol 28: 4670-4673.
5. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214.
6. James K, Eisenhauer E, Christian M, Terenziani M, Vena D, et al. (1999) Measuring response in solid tumours: unidimensional versus bidimensional measurement. J Natl Cancer Inst 91: 523-528.
7. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280.
8. Brada M, Yung WK (2000) Clinical trial end points in malignant glioma: need for effective trial design strategy. Semin Oncol 27: 11-19.
9. Galanis E, Buckner JC, Maurer MJ, Sykora R, Castillo R, et al. (2006) Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumour area, and computer-assisted tumour volume methods. Neuro Oncol 8: 156-165.
10. Van den Bent MJ, Vogelbaum MA, Wen PY, Macdonald DR, Chang SM (2009) End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. J Clin Oncol 27: 2905-2908.
11. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, et al. (2009) Guidelines for the evaluation of immune therapy activity in solid tumours: immune-related response criteria. Clin Cancer Res 15: 7412-7420.
12. Wheeler CJ, Black KL (2011) Vaccines for glioblastoma and high-grade glioma. Expert Rev Vaccines 10: 875-886.
13. Cairncross JG, Macdonald DR, Pexman JH, Ives FJ (1988) Steroid-induced CT changes in patients with recurrent malignant glioma. Neurology 38: 724-726.
14. Finn MA, Blumenthal DT, Salzman KL, Jensen RL (2007) Transient postictal MRI changes in patients with brain tumours may mimic disease progression. Surg Neurol 67: 246-250.
15. Henegar MM, Moran CJ, Silbergeld DL (1996) Early postoperative magnetic resonance imaging following nonneoplastic cortical resection. J Neurosurg 84: 174-179.
16. Taal W, Brandsma D, de Bruin HG, Bromberg JE, Swaak-Kragten AT, et al. (2008) Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 113: 405-410.
17. Watling CJ, Lee DH, Macdonald DR, Cairncross JG (1994) Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma. J Clin Oncol 12:1886-1889.
18. Dougan M, Dranoff G (2009) Immune therapy for cancer. Annu Rev Immunol 27: 83-117.
19. Van Baren N, Bonnet MC, Dreno B, Khammari A, Dorval T, et al. (2005) Tumoural and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol 23: 9008-9021.
20. Parney IF, Kunwar S, McDermott M, Berger M, Prados M, et al. (2005) Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. J Neurosurg 102: 267-275.
21. Smith MM, Thompson JE, Castillo M, Cush S, Mukherji SK, et al. (1996) MR of recurrent high-grade astrocytomas after intralesional immunotherapy. AJNR Am J Neuroradiol 17: 1065-1071.
22. Terasaki M, Shibui S, Narita Y, Fujimaki T, Aoki T, et al. (2011) Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme. J Clin Oncol 29: 337-344.
23. Ahmed R, Zha XM, Green SH, Dailey ME (2006) Synaptic activity and F-actin coordinately regulate CaMKIIalpha localization to dendritic postsynaptic sites in developing hippocampal slices. Mol Cell Neurosci 31: 37-51.
24. Bao L, Dunham K, Stamer M, Mulieri KM, Lucas KG (2008) Expansion of cytomegalovirus pp65 and IE-1 specific cytotoxic T lymphocytes for cytomegalovirus-specific immunotherapy following allogeneic stem cell transplantation. Biol Blood Marrow Transplant 14: 1156-1162.
25. Bao L, Sun Q, Lucas KG (2007) Rapid generation of CMV pp65-specific T cells for immunotherapy. J Immunother 30: 557-561.
26. Broder H, Anderson A, Kremen TJ, Odesa SK, Liau LM (2003) MART-1 adenovirus-transduced dendritic cell immunization in a murine model of metastatic central nervous system tumor. J Neurooncol 64: 21-30.
27. Choi BD, Archer GE, Mitchell DA, Heimberger AB, McLendon RE, et al. (2009) EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol 19: 713-723.
28. De Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van Loon J, et al. (2008) Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 14: 3098-3104.
29. Dillman RO, Duma CM, Schiltz PM, DePriest C, Ellis RA, et al. (2004) Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J Immunother 27: 398-404.
30. Heimberger AB, Crotty LE, Archer GE, Mc Lendon RE, Friedman A, et al. (2000) Bone marrow-derived dendritic cells pulsed with tumour homogenate induce immunity against syngeneic intracerebral glioma. J Neuroimmunol 103:16-25.
31. Heimberger AB, Sampson JH (2009) The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Expert Opin Biol Ther 9: 1087-1098.
32. Heimberger AB, Sun W, Hussain SF, Dey M, Crutcher L, et al. (2008) Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro Oncol 10: 98-103.
33. Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, et al. (2004) Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res 64: 9160-9166.
34. Liau LM, Jensen ER, Kremen TJ, Odesa SK, Sykes SN, et al. (2002) Tumor immunity within the central nervous system stimulated by recombinant Listeria monocytogenes vaccination. Cancer Res 62: 2287-2293.
35. Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, et al. (2005) Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11: 5515-5525.
36. Okada H, Lieberman FS, Walter KA, Lunsford LD, Kondziolka DS, et al. (2007) Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J Transl Med 5: 67.
37. Schmittling RJ, Archer GE, Mitchell DA, Heimberger A, Pegram C, et al. (2008) Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. J Immunol Methods 339: 74-81.
38. Sloan AE, Dansey R, Zamorano L, Barger G, Hamm C, et al. (2000) Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes. Neurosurg Focus 9: e9.
39. Wheeler CJ, Black KL, Liu G, Mazer M, Zhang XX, et al. (2008) Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res 68: 5955-5964.
40. Yajima N, Yamanaka R, Mine T, Tsuchiya N, Homma J, et al. (2005) Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res 11: 5900-5911.
41. Yu JS, Liu G, Ying H, Yong WH, Black KL, et al. (2004) Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64: 4973-4979.
42. Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, et al. (2001) Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61: 842-847.
43. Zitvogel L, Tesniere A, Apetoh L, Ghiringhelli F, Kroemer G (2008) [Immunological aspects of anticancer chemotherapy]. Bull Acad Natl Med 192: 1469-1487.
44. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G (2008) Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8: 59-73.
45. Antonia SJ, Mirza N, Fricke I, Chiappori A, Thompson P, et al. (2006) Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 12: 878-887.
46. Wheeler CJ, Das A, Liu G, Yu JS, Black KL (2004) Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 10: 5316-5326.
47. Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, et al. (2010) Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 28: 4722-4729.
48. (2009) Draft Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines, US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research.